"Partanen, Anu" - Selaus tekijän mukaan TUNICRIS-julkaisut

Viitteet 1-8 / 8

    • Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study 

      Turunen, Antti; Silvennoinen, Raija; Partanen, Anu; Valtola, Jaakko; Siitonen, Timo; Putkonen, Mervi; Sankelo, Marja; Pyörälä, Marja; Kuittinen, Taru; Penttilä, Karri; Sikiö, Anu; Savolainen, Eeva Riitta; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; Jantunen, Esa (05 / 2021)
      article
      <p>Background: Autologous stem cell transplantation (auto-SCT) is a widely used treatment option in multiple myeloma (MM) patients. The optimal graft cellular composition is not known. Study design and methods: ...

    • Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial 

      Kytölä, Sari; Kurkela, Mika; Kiiski, Johanna I; Vänttinen, Ida; Ruokoranta, Tanja; Partanen, Anu; Holopainen, Annasofia; Pyörälä, Marja; Kuusisto, Milla E  L; Siitonen, Timo; Koskela, Sirpa; Rimpiläinen, Johanna; Ettala, Pia; Kuusanmäki, Heikki; Niemi, Mikko; Backman, Janne T; Kontro, Mika (06 / 2025)
      article
      Venetoclax has improved outcomes for acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy. Managing cytopenias and infections remains challenging. Previous pharmacokinetic studies have shown considerable ...

    • CD34<sup>+</sup>Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients 

      Turunen, Antti Samuli; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Penttilä, Karri; Harmanen, Minna; Keskinen, Leena; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; Jantunen, Esa; Partanen, Anu (2023)
      article
      &lt;p&gt;Backgound: Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy. Study Design and Methods: This prospective ...

    • Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy 

      Luoma, Sini; Sergeev, Philipp; Javarappa, Komal Kumar; Öhman, Tiina J.; Varjosalo, Markku; Säily, Marjaana; Anttila, Pekka; Sankelo, Marja; Partanen, Anu; Nihtinen, Anne; Heckman, Caroline A.; Silvennoinen, Raija (05 / 2023)
      article
      The bone marrow microenvironment interacts with malignant cells and regulates cancer survival and immune evasion in multiple myeloma (MM). We investigated the immune profiles of longitudinal bone marrow samples from patients ...

    • Evolution of treatment practices and outcomes in multiple myeloma during 2013-2022: a Finnish real world registry study 

      Partanen, Anu; Waltari, Marika; Vikkula, Johanna; Mattila, Riikka; Närhi, Katja; Eeva, Jonna; Putkonen, Mervi (05.05.2025)
      article
      BACKGROUND AND PURPOSE: Multiple myeloma (MM) is a heterogenous hematologic malignancy with an evolving treatment landscape. This Finnish real-world evidence study clarifies the evolution of treatment practices and outcomes ...

    • Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group 

      Partanen, Anu; Waage, Anders; Peceliunas, Valdas; Schjesvold, Fredrik; Anttila, Pekka; Säily, Marjaana; Uttervall, Katarina; Putkonen, Mervi; Carlson, Kristina; Haukas, Einar; Sankelo, Marja; Szatkowski, Damian; Hansson, Markus; Marttila, Anu; Svensson, Ronald; Axelsson, Per; Lauri, Birgitta; Mikkola, Maija; Karlsson, Conny; Abelsson, Johanna; Ahlstrand, Erik; Sikiö, Anu; Klimkowska, Monika; Matuzeviciene, Reda; Fenstad, Mona Hoysaeter; Ilveskero, Sorella; Pelliniemi, Tarja Terttu; Nahi, Hareth; Silvennoinen, Raija (03 / 2024)
      article
      Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study enrolled 120 transplant-eligible NDMM patients. The treatment ...

    • Miten turvataan myelooman yhdenvertainen hoito tulevaisuudessa? 

      Silvennoinen, Raija; Anttila, Pekka; Lievonen, Juha; Sankelo, Marja; Säily, Marjaana; Partanen, Anu; Putkonen, Mervi (2022)
      reviewarticle
      • Myelooman vuosittainen ilmaantuvuus on pysynyt vakaana, mutta kehittyneiden hoitojen ansiosta potilaiden elinikä pitenee. Siksi hoidossa olevien potilaiden määrä kasvaa. • Kliinisen hematologian erikoislääkärien määrän ...

    • Switching From Standard to Extended Half-Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland 

      Koivusalo, Mirkka; Szanto, Timea; Kovalainen, Tuomas; Vesikansa, Aino; Laine, Outi; Partanen, Anu; Siitonen, Timo; Vesanen, Marko; Mehtälä, Juha; Sarnesto, Nina; Haapkylä, Johanna; Lehtinen, Anna Elina; Lassila, Riitta (2025)
      article
      Introduction: Real-world data are needed to evaluate treatment implementation, outcomes and costs of care in haemophilia patients switching prophylaxis from standard half-life (SHL) to extended half-life (EHL) clotting ...